Abstract:Bladder cancer (BC) is one of the most prevalent malignancies globally. Despite recent advancements, resistance to conventional treatments such as surgery, chemotherapy, and immunotherapy remains common among BC patients. Thus, developing novel therapeutic agents or enhancing the efficacy of current treatments is essential for better management of BC. Oncolytic adenoviruses represent a promising new approach, capable of inflaming the tumor microenvironment and eliciting tumor-specific T cell responses. In this study, we aimed to understand the immune mechanisms involved in the antitumor therapeutic efficacy of oAd/IL-12/shVEGF—an oncolytic adenovirus co-expressing interleukin-12 (IL-12) and short hairpin RNA targeting vascular endothelial growth factor (shVEGF)—both in vitro and in vivo against BC. To investigate the therapeutic potential of oAd/IL-12/shVEGF in a syngeneic MB49 BC model, tumor-bearing mice were intratumorally injected with the oncolytic virus when tumors reached 70-100 mm3. Tumor volume and body weight were monitored until the end of the experiment. Mice were sacrificed when tumors reached 2000 mm3, and both tumor and spleen tissues were disaggregated for analysis. Tumor tissues were examined for proliferation marker (PCNA), adenovirus injection marker (E1A), and antitumor immune marker (CD8) using H&E and immunohistochemical analysis. To evaluate immune modulation, levels of IFN-γ, TNF-α, and IL-12 in tumor tissues and splenocytes were measured using ELISA kits. Tumor-specific immune responses were assessed by evaluating the number of IFN-γ-secreting immune cells in splenocytes via ELISPOT assay. Statistical analysis was performed using one-way ANOVA. Treatment with oAd/IL-12/shVEGF significantly suppressed tumor growth compared to PBS-treated controls. The oncolytic virus increased levels of IFN-γ, TNF-α, and IL-12 in both tumor tissues and splenocytes compared to PBS. Additionally, oAd/IL-12/shVEGF enhanced CD8+ T cell infiltration into tumor tissues and significantly reduced PCNA expression, indicating decreased tumor cell proliferation. Consistent with these findings, the number of IFN-γ-secreting immune cells was significantly higher in mice treated with oAd/IL-12/shVEGF compared to those treated with PBS. These results suggest that oAd/IL-12/shVEGF is a promising clinical cancer immunotherapeutic agent for inducing antitumor immunity in bladder cancer. Citation Format: Yunlim Kim, Bum Jin Lim, A-Rum Yoon, Chae-Ok Yun, Choung-Soo Kim. Oncolytic adenovirus induces potent anti-tumor efficacy via robust activation of immune cells in bladder cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A058.

AB087. the Biotherapy for Bladder Cancer

Antitumor Effects of Bladder Cancer-Specific Adenovirus Carrying E1A-androgen Receptor in Bladder Cancer

Effect of Combined Treatment of Radiation and Tissue-Specific Recombinant Oncolytic Adenovirus on Bladder Cancer Cells

Synergistic Effect of Bladder Cancer-Specific Oncolytic Adenovirus in Combination with Chemotherapy.

Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice.

Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro

A Novel Bladder Cancer - Specific Oncolytic Adenovirus by CD46 and Its Effect Combined with Cisplatin Against Cancer Cells of CAR Negative Expression

Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment

Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancer

Raav9-Upii-tk-egfp Can Precisely Transduce a Suicide Gene and Inhibit the Growth of Bladder Tumors.

Revitalizing Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches

Oct4 and Hypoxia Dual-Regulated Oncolytic Adenovirus Armed with shRNA-Targeting Dendritic Cell Immunoreceptor Exerts Potent Antitumor Activity against Bladder Cancer

Abstract A058: Oncolytic adenovirus induces potent anti-tumor efficacy via robust activation of immune cells in bladder cancer

Fiber-modified Adenovirus-Mediated Suicide Gene Therapy Can Efficiently Eliminate Bladder Cancer Cells in Vitro and in Vivo

Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment

Homologous Targeting and Adhesion Abilities of Cellular Microvesicles for Enhanced Intravesical Therapy of Bladder Cancer

Intravesical Pseudomonas Aeruginosa Mannose-Sensitive Hemagglutinin Vaccine Triggers a Tumor-Preventing Immune Environment in an Orthotopic Mouse Bladder Cancer Model.

Adenovirus-mediated Transfer of P53 and P16 Inhibiting Proliferating Activity of Human Bladder Cancer Cell EJ in Vitro and in Vivo

Engineered VNP20009 Expressing IL-15&15Rα Augments Anti-Tumor Immunity for Bladder Cancer Treatment

Adenovirus-mediated HSV-tk Gene Therapy for Experimental Human Bladder Cancer

Advances and future prospects of immunotherapy in bladder cancer